[Federal Register Volume 66, Number 30 (Tuesday, February 13, 2001)]
[Notices]
[Pages 10028-10029]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-3606]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

The ImmunoChip

Matthias Lorenz (NCI)
DHHS Reference No. E-288-00/0 filed 29 Dec 2000

    Licensing Contact: Richard Rodriguez; 301/496-7056 ext. 287; e-
mail: <a href="/cdn-cgi/l/email-protection#88fae7ecfae1effdfac8e7eca6e6e1e0a6efe7fe"><span class="__cf_email__" data-cfemail="d5a7bab1a7bcb2a0a795bab1fbbbbcbdfbb2baa3">[email protected]</span></a>.
    The inventors have established a method to select sequences from 
databases for the construction of custom microarrays. Using this 
method, an immunological relevant microarray (ImmunoChip) was 
constructed. The ImmunoChip is a cDNA microarray which contains more 
than 13,000 different murine immunological-relevant genetic probes. The 
ImmunoChip can be used to study gene expression of immune cells or 
immune infiltrating tissues and organs. Specifically, the chip could be 
used for immunologically related research and/or vaccine development 
for a variety of human diseases which would include, but not 
necessarily limited to, cancer, infectious diseases, autoimmune 
diseases and allergies.

Water Soluble Amino Acid Analogs of Aminoflavone Compounds

Kenneth M. Snader et al. (NCI)
DHHS Reference No. E-279-99/0 filed 06 Apr 2000

    Licensing Contact: Girish Barua; 301/496-7735 ext. 263; e-mail: 
<a href="/cdn-cgi/l/email-protection#b2d0d3c0c7d3d5f2ddd69cdcdbda9cd5ddc4"><span class="__cf_email__" data-cfemail="bddfdccfc8dcdafdd2d993d3d4d593dad2cb">[email protected]</span></a>.
    Many potential drugs of cancer chemotherapy intended for parenteral 
administration have been abandoned because the active ingredient is 
either slightly soluble or water-insoluble. Various methods have been 
developed to improve water solubility of these drugs. However, these 
methods can be complex and have a negative impact resulting from the 
use of co-solvents and complexing agents. The present invention 
addresses these problems by providing a method of producing water-

[[Page 10029]]

soluble analogues of water-insoluble drugs.
    In particular, the present invention describes novel analogues 
derived from 5-aminoflavone (TK2339) compounds. These derivatives have 
shown good differential activity in the NCI 60-cell line in vitro 
cancer drug screen with potent and selective cytotoxicity against CAKI-
1 and A498 renal, MCF-7 breast, and OVCAR-5 ovarian carcinoma cell 
lines. In addition, these derivatives have shown in vivo activity 
against CAKI-1 and A498 renal carcinoma xenographs.
    To overcome poor solubility of many members of the flavone class of 
compounds, a series of more hydrophilic, polar conjugates were prepared 
which are capable of forming soluble salts. These novel compounds 
display improved solubility in aqueous solutions over the parent 
compound without sacrificing potent antitumor activity. Since these 
compounds possess very favorable pharmaceutical properties, they have 
the greater potential to be useful in the treatment of human cancers.

    Dated: February 2, 2001.
Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 01-3606 Filed 2-12-01; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>